摘要 Objective: Late-onset hypogonadism, or androgen deficiency in the aging male, is a significant cause of morbidity in older men. Many men in the low normal or equivocal range for low testosterone level exhibit signs and symptoms of hypogonadism. Serum testosterone is an imperfect maker for hypogonadism as symptoms vary greatly within the low to low normal range in addition to variations among testosterone assays. Perineal ultrasound can be effectively used to examine the bulbocavernosus muscle (BCM), an androgenized tissue that may be impacted by androgen receptor activity.Methods: This study was a retrospective analysis of men who underwent perineal ultrasound for hypogonadism. The ultrasound data were used to calculate the area of the BCM and correlate it with indices of hypogonadismin symptomatic men including free and total testosterone and dual-energy X-ray absorptiometry (DEXA).Results: The results demonstrate that there is a significant correlation between total and free testosterone and BCM area in hypogonadal patients. Comparison between BCM area and total testosterone showed R2=0.061 and P=0.0187 and comparison between BCM area and free testosterone showed R2=0.0957 and P=0.0034. In addition, low BCM was also correlated with DEXA results showing osteoporosis and osteopenia (R2=0.2239, P=0.0027)..Conclusion: There has been recent controversy over the safety of testosterone replacement therapy. This might be particularly important in men with hypogonadal symptoms but a low normal testosterone level. Our study investigated the use of perineal ultrasound to measure BCM as a surrogate marker for poor androgenized men presenting with hypogonadism.
Abstract: Objective: Late-onset hypogonadism, or androgen deficiency in the aging male, is a significant cause of morbidity in older men. Many men in the low normal or equivocal range for low testosterone level exhibit signs and symptoms of hypogonadism. Serum testosterone is an imperfect maker for hypogonadism as symptoms vary greatly within the low to low normal range in addition to variations among testosterone assays. Perineal ultrasound can be effectively used to examine the bulbocavernosus muscle (BCM), an androgenized tissue that may be impacted by androgen receptor activity.Methods: This study was a retrospective analysis of men who underwent perineal ultrasound for hypogonadism. The ultrasound data were used to calculate the area of the BCM and correlate it with indices of hypogonadismin symptomatic men including free and total testosterone and dual-energy X-ray absorptiometry (DEXA).Results: The results demonstrate that there is a significant correlation between total and free testosterone and BCM area in hypogonadal patients. Comparison between BCM area and total testosterone showed R2=0.061 and P=0.0187 and comparison between BCM area and free testosterone showed R2=0.0957 and P=0.0034. In addition, low BCM was also correlated with DEXA results showing osteoporosis and osteopenia (R2=0.2239, P=0.0027)..Conclusion: There has been recent controversy over the safety of testosterone replacement therapy. This might be particularly important in men with hypogonadal symptoms but a low normal testosterone level. Our study investigated the use of perineal ultrasound to measure BCM as a surrogate marker for poor androgenized men presenting with hypogonadism.
通讯作者:
Bruce R. Gilbert, E-mail address:bgilbert@gmail.com
E-mail: bgilbert@gmail.com
引用本文:
Nikhil Gupta, Maria Carvajal, Michael Jurewicz, Bruce R. Gilbert. Bulbocavernosus muscle area as a novel marker for hypogonadism[J]. Asian Journal of Urology, 2017, 4(1): 3-9.
Nikhil Gupta, Maria Carvajal, Michael Jurewicz, Bruce R. Gilbert. Bulbocavernosus muscle area as a novel marker for hypogonadism. Asian Journal of Urology, 2017, 4(1): 3-9.
[1] Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years:the HIM study. Int J Clin Pract 2006;60:762e9. [2] Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men:estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004;89:5920e6. [3] Araujo AB, Esche GR, Kupelian V, O'Donnell AB, Travison TG, Williams RE, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007;92:4241e7. [4] Ye F, McCoy SC, Ross HH, Bernardo JA, Beharry AW, Senf SM, et al. Transcriptional regulation of myotrophic actions by testosterone and trenboone on androgen-responsive muscle. Steroids 2014;87:59e66. [5] Cristina RT, Hanganu F, Dumitrescu E, Muselin F, Butnariu M, Constantin A, et al. The impact of exogenic testosterone and nortestosterone-decanoate toxicological evaluation using a rat model. PLoS One 2014;9:e109219. [6] Dabaja AA, Wosnitzer MS, Mielnik A, Bolyakov A, Schlegel PN, Paduch DA. Bulbocavernosus muscle area measurement:a novel method to assess androgenic activity. Asian J Androl 2014;16:618e22. [7] Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999;84:1966e72. [8] Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996;81:4358e65. [9] Coluzzi F, Pergolizzi J, Raffa RB, Mattia C. The unsolved case of "bone-impairing analgesics":the endocrine effects of opioids on bone metabolism. Ther Clin Risk Manag 2015;11:515e23. [10] Cookson J, Hodgson R, Wildgust HJ. Prolactin, hyperprolactinaemia and antipsychotic treatment:a review and lessons for treatment of early psychosis. J Psychopharmacol 2012;26:42e51. [11] Nenonen HA, Giwercman A, Hallengren E, Giwercman YL. Non-linear association between androgen receptor CAG repeat length and risk of male subfertility-a meta-analysis. Int J Androl 2011;34:327e32. [12] Paduch DA, Brannigan RE, Fuchs EF, Kim E, Marmar JL, Sandlow JI. The laboratory diagnosis of testosterone deficiency. AUA White Papers; 2013. https://www.auanet.org/common/pdf/education/clinical-guidance/TestosteroneDeficiency-WhitePaper.pdf. [13] FDA briefing document for the joint meeting for Bone, Reproductive, and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management Advisory Committee (DSARMAC). Silver Spring, MD:FDA Advisory Committee; September 17, 2014. https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/eproductiveHealthDrugsAdvisoryCommittee/UCM41236.pdf. [14] Nguyen CP, Hirsch MS, Money D, Kaul S, Mohamoud M, Joffe HV. Testosterone and "age-related hypogonadism"-FDA concerns. N Engl J Med 2015;373:689e91. [15] Brock G, Heiselman D, Maggi M, Kim SW, Rodrıíguez Vallejo JM, Behre HM, et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men:results of a placebo controlled study. J Urol 2016;195:699e705. [16] Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephens-Shields AJ, Cauley JA, et al. Effects of testosterone treatment in older men. N Engl J Med 2016;374:611e24. [17] Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med 2010;363:109e22. [18] Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014;9:e85805. [19] Vigen R, O'Donnell CI, Baron AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013;310:1829e36. [20] Sharma R, Oni OA, Gupta K, Chen G, Sharma M, Dawn B, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J 2015;36:2706e15. [21] Morgentaler A, Miner MM, Caliber M, Guay AT, Khera M, Traish AM. Testosterone therapy and cardiovascular risk:advances and controversies. Mayo Clin Proc 2015;90:224e51. [22] Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E, et al. Cardiovascular risk associated with testosterone-boosting medications:a systematic review and meta-analysis. Expert Opin Drug Saf 2014;13:1327e51. [23] Fu L, Gao QP, Shen JX. Relationship between testosterone and indexes indicating endothelial function in male coronary heart disease patients. Asian J Androl 2008;1:214e8. [24] Traish AM. Testosterone and weight loss:the evidence. Curr Opin Endocrinol Diabetes Obes 2014;21:313e22.
Christopher Hartman, Nikhil Gupta, David Leavitt, David Hoenig, Zeph Okeke, Arthur Smith. Advances in percutaneous stone surgery[J]. Asian Journal of Urology, 2015, 2(1): 26
-32
.
